Oasmia appoints E. Öhman J:or Fondkommission AB as market maker and financial
advisor as well as forwards the publication of the interim report
Oasmia Pharmaceutical AB (publ) has appointed E. Öhman J:or Fondkommission AB
as market maker for the Oasmia share which is listed on NGM Equity. The purpose
is to reduce the difference between bid and ask price and increase the
liquidity of the share.
Oasmia has previously started a process to change stock exchange listing to the
main list of NASDAQ OMX Stockholm because the company considers NASDAQ OMX to
be a more suitable stock exchange for the company's shares. The market maker
commitment begins on 1 December 2008 and for a start it applies to the trading
on NGM Equity, and if a change of listing to NASDAQ OMX occurs during the term
of the agreement, the trading on NASDAQ OMX.
Oasmia has also appointed Öhman as financial advisor in connection to the
transfer to NASDAQ OMX and a long-term collaboration concerning capital market
activities has been initiated to improve the scope of the company's information
to shareholders and other interested parties.
In connection to this Oasmia brings forward the publication of the interim
report for the period May - October 2008. The company has previously reported
publication on 18 December 2008. The new date of publication is 10 December
2008.
For further information, please contact
Julian Aleksov, CEO, Oasmia Pharmaceutical AB, telephone: +46 (0)18 50 54 40
Concerning liquidity guarantee
Joakim Appeltofft, E. Öhman J:or Fondkommission AB, telephone: +46 (0)40 750 20
For more information, please contact: Maria Lundén, Head of Public Relations,
Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40.
Information is also available at www.ngm.se and www.oasmia.com
